Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistry.
Whaley RD, Sill DR, Tekin B, McCarthy MR, Cheville JC, Ebare K, Stanton ML, Reynolds JP, Raghunathan A, Herrera Hernandez LP, Jimenez RE, Sharma V, Boorjian SA, Leibovich BC, Hofich CD, Alvand S, Pujari GP, Kipp BR, Ketterling RP, Geiersbach KB, Greipp PT, Sukov WR, Halling KC, Gupta S.
Whaley RD, et al.
Hum Pathol. 2025 May;159:105797. doi: 10.1016/j.humpath.2025.105797. Epub 2025 May 15.
Hum Pathol. 2025.
PMID: 40381702
TFE3-RCC fusion partners included RBM10, NONO, ASPSCR1, FUBP1, SFPQ, MAPK1IP1L, and PRCC. TFEB-rearranged RCC fusion partners SYNRG and BYSL were identified. Diffuse GPNMB expression was seen in 92% of TFE3-RCC (24/26; median H-score 275), 100% of TFEB-rearranged RCC (19/1 …
TFE3-RCC fusion partners included RBM10, NONO, ASPSCR1, FUBP1, SFPQ, MAPK1IP1L, and PRCC. TFEB-rearranged RCC fusion partners SYNRG a …